{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:18:28Z","timestamp":1779344308822,"version":"3.51.4"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recent evidence has suggested that primary aldosteronism (PA) is the predominant cause of secondary hypertension and is linked to adverse left ventricular (LV) remodeling. However, few studies have investigated the potential associations of aldosterone-to-renin ratio (ARR), an important parameter for PA screening, with the risk of adverse LV remodeling in the Chinese population. This study aimed to investigate the associations of ARR, plasma aldosterone concentration (PAC), and plasma renin concentration (PRC) with adverse LV remodeling in a population from Guangxi, China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The analyzed data were primarily obtained from the First Affiliated Hospital of Guangxi Medical University and the First People\u2019s Hospital of Yulin City during the period from September 2022 to March 2024. A total of 724 participants (mean age: 56.4\u202f\u00b1\u202f14.3\u202fyears, 71% with hypertension) who underwent aldosterone\u2013renin testing and echocardiography were included in the study. Data on demographics, clinical history, and medications, including calcium channel blockers and mineralocorticoid receptor antagonists (MRAs), were collected. We applied a generalized linear model (GLM) and a multivariable logistic regression model to estimate the relationships between ARR, PAC, and PRC with the risk of adverse LV remodeling and left ventricular hypertrophy (LVH) and further explored the dose\u2013response relationship.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 724 participants included in this study, GLM revealed that ARR was associated with greater left atrium size, left ventricular end-diastolic diameter, left ventricular mass, and left ventricular mass index. In adjusted multivariable regression analyses, one standard deviation (SD) of ARR emerged as a significant predictor of LVH occurrence [OR\u202f=\u202f1.531 (95%CI, 1.041\u20132.251),\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.030], and compared with the first tertile of ARR, the third tertile of ARR had a 2.106-fold higher risk of LVH (\n                      <jats:italic>p<\/jats:italic>\n                      -trend &amp;lt;0.05), especially in participants without mineralocorticoid receptor antagonists (MRA). Furthermore, a significant dose\u2013response relationship was observed between ARR and LVH risk (\n                      <jats:italic>p<\/jats:italic>\n                      overall &amp;lt;0.001,\n                      <jats:italic>p<\/jats:italic>\n                      non-linear\u202f=\u202f0.079;\n                      <jats:italic>p<\/jats:italic>\n                      overall tests the overall association, while\n                      <jats:italic>p<\/jats:italic>\n                      non-linear tests for a non-linear trend between ARR and LVH risk).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Elevated ARR is associated with an increased risk of adverse LV remodeling, and the presence of LVH may even occur at ARR levels below the clinical standard range, suggesting that ARR could serve as an early indicator of cardiac structural changes. Our results revealed that earlier targeted intervention with MRAs may be beneficial. However, this hypothesis requires confirmation in prospective and interventional studies, particularly those assessing the clinical and cost-effectiveness of early MR blockade. Our study provided a foundation for further exploration of this approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1703635","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:51:37Z","timestamp":1767768697000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Elevated plasma aldosterone-to-renin ratio as a potential risk marker of adverse left ventricular remodeling: a cross-sectional study"],"prefix":"10.3389","volume":"12","author":[{"given":"Mingjie","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushuang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingli","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zengnan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boteng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/s0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"Zhou","year":"2021","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41569-018-0119-4","article-title":"Epidemiology of cardiovascular disease in China: current features and implications","volume":"16","author":"Zhao","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary Aldosteronism: an Endocrine Society clinical practice guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.jacc.2020.02.052","article-title":"Primary aldosteronism in patients in China with recently detected hypertension","volume":"75","author":"Xu","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"H2372","DOI":"10.1152\/ajpheart.00283.2011","article-title":"A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone","volume":"301","author":"L\u00f3pez-Andr\u00e9s","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41371-020-00426-y","article-title":"Left ventricular remodeling and dysfunction in primary aldosteronism","volume":"35","author":"Tsai","year":"2021","journal-title":"J Hum Hypertens"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1161\/circulationaha.123.066389","article-title":"Subclinical primary aldosteronism and cardiovascular health: a population-based cohort study","volume":"149","author":"Hundemer","year":"2024","journal-title":"Circulation"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1161\/hypertensionaha.118.12342","article-title":"Aldosterone induces vascular damage","volume":"74","author":"Hung","year":"2019","journal-title":"Hypertension"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"200138","DOI":"10.1016\/j.ijcrp.2022.200138","article-title":"Relationship between plasma aldosterone levels and arterial stiffness parameters in hypertensive patients with subclinical vascular damage","volume":"14","author":"Petramala","year":"2022","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s41371-021-00639-9","article-title":"Assessment of skin microcirculation in primary aldosteronism: impaired microvascular responses compared to essential hypertensives and normotensives","volume":"36","author":"Gkaliagkousi","year":"2022","journal-title":"J Hum Hypertens"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1161\/hypertensionaha.116.08952","article-title":"Continuum of renin-independent aldosteronism in normotension","volume":"69","author":"Baudrand","year":"2017","journal-title":"Hypertension"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1161\/hypertensionaha.120.15006","article-title":"Serum aldosterone concentration, blood pressure, and coronary artery calcium: the multi-ethnic study of atherosclerosis","volume":"76","author":"Inoue","year":"2020","journal-title":"Hypertension"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e004815","DOI":"10.1161\/circimaging.116.004815","article-title":"Cardiac remodeling in patients with primary and secondary aldosteronism: a tissue Doppler study","volume":"9","author":"Cesari","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1470320310376424","article-title":"Factors influencing left ventricular mass regression in patients with primary aldosteronism post adrenalectomy","volume":"12","author":"Lin","year":"2011","journal-title":"J Renin-Angiotensin-Aldosterone Syst"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1210\/jc.2016-3867","article-title":"Renin phenotypes characterize vascular disease, autonomous aldosteronism, and mineralocorticoid receptor activity","volume":"102","author":"Hundemer","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","first-page":"727","article-title":"Expert consensus on the diagnosis and treatment of primary aldosteronism (2020 edition)","volume":"36","year":"2020","journal-title":"Chin J Endocrinol Metab"},{"key":"ref18","first-page":"505","article-title":"Chinese expert consensus on precision diagnosis and treatment of hypertension (2024)","volume-title":"Chin J Hypertens","author":"Zeng","year":"2024"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1161\/01.cir.55.4.613","article-title":"Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method","volume":"55","author":"Devereux","year":"1977","journal-title":"Circulation"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3760\/cma.j.cn112148-20240709-00377","article-title":"Clinical practice guidelines for the management of hypertension in China","volume":"52","year":"2024","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/ajh\/hpz023","article-title":"The aldosterone\/renin ratio predicts cardiometabolic disorders in subjects without classic primary aldosteronism","volume":"32","author":"Vecchiola","year":"2019","journal-title":"Am J Hypertens"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/01.hyp.27.5.1039","article-title":"Changes in left ventricular anatomy and function in hypertension and primary aldosteronism","volume":"27","author":"Rossi","year":"1996","journal-title":"Hypertension"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1161\/hypertensionaha.107.095448","article-title":"Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism","volume":"50","author":"Catena","year":"2007","journal-title":"Hypertension"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fcvm.2014.00007","article-title":"Electrical and myocardial remodeling in primary Aldosteronism","volume":"1","author":"Curione","year":"2014","journal-title":"Front Cardiovasc Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"22:e013263","DOI":"10.1161\/jaha.119.013263","article-title":"Left ventricular dysfunction in patients with primary aldosteronism: a propensity score-matching follow-up study with tissue Doppler imaging","volume":"8","author":"Chang","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/nm.2506","article-title":"Oxidation of CaMKII determines the cardiotoxic effects of aldosterone","volume":"17","author":"He","year":"2011","journal-title":"Nat Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"20406223221143253","DOI":"10.1177\/20406223221143253","article-title":"Anatomical and functional remodeling of left ventricle in patients with primary aldosteronism and concomitant albuminuria","volume":"14","author":"Kao","year":"2023","journal-title":"Ther Adv Chronic Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1161\/hypertensionaha.119.14601","article-title":"Nadir aldosterone levels after confirmatory tests are correlated with left ventricular hypertrophy in primary aldosteronism","volume":"75","author":"Ohno","year":"2020","journal-title":"Hypertension"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2174\/1570161115666170426145612","article-title":"Clinical value of measuring the renin\/aldosterone levels: optimising the management of uncontrolled\/resistant hypertension","volume":"16","author":"Doumas","year":"2017","journal-title":"Curr Vasc Pharmacol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/s0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1161\/hypertensionaha.120.14811","article-title":"Autonomous aldosterone production and left ventricular hypertrophy","volume":"75","author":"Tu","year":"2020","journal-title":"Hypertension"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/eurheartj\/ehv548","article-title":"Heart failure: when form fails to follow function","volume":"37","author":"Katz","year":"2016","journal-title":"Eur Heart J"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/ndt\/gfs587","article-title":"Regression of left ventricular hypertrophy in patients with primary aldosteronism\/low-renin hypertension on low-dose spironolactone","volume":"28","author":"Ori","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1161\/hypertensionaha.108.114140","article-title":"Inappropriate left ventricular mass in patients with primary aldosteronism","volume":"52","author":"Muiesan","year":"2008","journal-title":"Hypertension"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"630","DOI":"10.7326\/m17-0882","article-title":"The Spectrum of subclinical primary Aldosteronism and incident hypertension: a cohort study","volume":"167","author":"Brown","year":"2017","journal-title":"Ann Intern Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1210\/er.2018-00139","article-title":"The expanding Spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1210\/clinem\/dgac649","article-title":"Implication of MR activity in posttreatment arterial stiffness reversal in patients with primary aldosteronism","volume":"108","author":"Chen","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1161\/hypertensionaha.121.18118","article-title":"Screening rates for primary Aldosteronism among individuals with hypertension plus hypokalemia: a population-based retrospective cohort study","volume":"79","author":"Hundemer","year":"2022","journal-title":"Hypertension"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1703635\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:51:43Z","timestamp":1767768703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1703635\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":39,"alternative-id":["10.3389\/fmed.2025.1703635"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1703635","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"article-number":"1703635"}}